AMOYTOP BIOTECH

What AMOYTOP BIOTECH does

AMOYTOP Biotech (Xiamen Amoytop Biotech Co., Ltd. / 厦门特宝生物工程股份有限公司) is an innovative Chinese biopharmaceutical company founded in 1996 and publicly listed on the Shanghai Stock Exchange STAR Market (科创板) under ticker 688278. Headquartered in Xiamen, Fujian Province, with 501-1000 employees, the company specializes in the research, development, manufacturing, and commercialization of recombinant protein drugs and their long-acting PEGylation modifications, targeting chronic viral hepatitis, malignant tumors, and immunotherapy applications.

The company's technology platform centers on a proprietary Y-shaped 40kD PEG modification technology that enables precise connection at high-activity regions while avoiding the drug's core active area, preserving activity and reducing immunogenicity. This platform supports six marketed products: 派格宾® (Peginterferon alfa-2b), the world's first 40kD PEGylated interferon alfa-2b for chronic hepatitis B clinical cure and approved as the first product for HBsAg sustained clearance combined with nucleos(t)ide analogs; 益佩生® (Inpegsomatropin), the world's first Y-type 40kD PEGylated long-acting growth hormone approved in 2025; 珮金® (Telpegfilgrastim), a long-acting G-CSF launched in 2023; and three legacy cytokine products (特尔立®/Molgramostim, 特尔津®/Filgrastim, 特尔康®/Oprelvekin). The pipeline targets chronic hepatitis B clinical cure through multiple mechanisms — ACT201 (antisense oligonucleotide), ALG-000184 (capsid assembly modulator with NMPA Breakthrough Therapy designation), ACT560 (ALPK1 agonist), and ACT400 (mRNA therapeutic vaccine) — and is expanding into non-GHD short stature indications.

Revenue is generated through pharmaceutical product sales distributed via hospital procurement, China's Class B National Medical Insurance reimbursement system (covering multiple products), physician marketing through medical representatives, and emerging internet hospital platforms. The company holds patents across China, Europe, USA, and Japan, holds National Innovative Enterprise and National Intellectual Property Advantage Enterprise designations, and in April 2026 secured an exclusive Greater China license for Aligos Therapeutics' pevifoscorvir sodium (chronic HBV) for $25M upfront plus up to $420M in milestones and tiered royalties.

Name

AMOYTOP BIOTECH

Legal name

厦门特宝生物工程股份有限公司 (Xiamen Amoytop Biotech Co., Ltd.)

Website

https://amoytop.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

AMOYTOP Biotech is a publicly listed Chinese biopharmaceutical company developing proprietary Y-shaped 40kD PEGylated long-acting recombinant protein drugs for chronic hepatitis B, pediatric growth disorders, and oncology supportive care, with six marketed products.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — recombinant protein drugs

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIAAAI

Gastroenterology & Hepatology Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIAAAJ

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIACAI

Hematology Specialty Pharmaceuticals (Non-malignant)

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

SECONDARYHLAAADAF

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)

Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

• Recombinant protein drugs
• PEGylated long-acting drugs
• Hepatitis B therapeutics
• Growth hormone injections
• Cytokine biopharmaceuticals

Headquarters

HQ city

Xiamen

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Sale of innovative recombinant protein drugs including Peginterferon alfa-2b, growth hormone, G-CSF, GM-CSF, IL-11, and other cytokine biologics. Multiple products are covered under China's National Medical Insurance Catalog (Class B).

Distribution channels3 records

Marketing channels4 records

Core offering

AMOYTOP Biotech is a Chinese innovative biopharmaceutical company that researches, develops, manufactures, and sells recombinant protein drugs and their long-acting PEGylated versions. Its marketed portfolio of six products treats chronic hepatitis B (Peginterferon alfa-2b), pediatric growth hormone deficiency (Inpegsomatropin), chemotherapy-induced neutropenia (Telpegfilgrastim, Filgrastim), leukopenia (Molgramostim), and thrombocytopenia (Oprelvekin). The company is positioning its pipeline to pursue functional cure of chronic hepatitis B through multiple mechanisms including antisense oligonucleotides, capsid assembly modulators, immune agonists, and mRNA therapeutic vaccines.

Product overview

Amoytop Biotech is an innovative biopharmaceutical company specializing in R&D, manufacturing and marketing of recombinant protein drugs and their long-acting modifications, with a focus on immune-related cytokine medicines. The company offers a portfolio of 6 marketed products covering viral hepatitis and malignant tumor treatment areas: 派格宾® (Peginterferon alfa-2b) for chronic hepatitis B clinical cure; 益佩生® (Inpegsomatropin) for growth hormone deficiency; 珮金® (Telpegfilgrastim) for neutropenia; and three cytokine products 特尔立® (Molgramostim), 特尔津® (Filgrastim), and 特尔康® (Oprelvekin) for various hematological indications. The chronic hepatitis B clinical pipeline includes ACT201 (antisense oligonucleotide), ALG-000184 (capsid assembly modulator), ACT560 (ALPK1 agonist), and ACT400 (mRNA therapeutic vaccine), targeting full-population clinical cure of chronic hepatitis B.

Differentiator

Problem solved

Functional benefit

Brands

• 派格宾®: Peginterferon alfa-2b Injection - China's first domestically developed 40kD PEGylated long-acting interferon for chronic hepatitis B treatment. Class 1 new drug, launched 2016.
• 益佩生®
• 珮金®
• 特尔立®
• 特尔津®
• 特尔康®

Products and services

• 派格宾® (Peginterferon alfa-2b Injection) Peginterferon alfa-2b Injection (Class 1 new therapeutic biological product) for chronic hepatitis B, providing dual action of viral replication suppression and immune enhancement; first approved product for HBsAg sustained clearance in combination with nucleos(t)ide analogs in adult chronic hepatitis B patients.
• 益佩生® (Inpegsomatropin Injection) Inpegsomatropin Injection (Class 1 new therapeutic biological product) for growth retardation due to growth hormone deficiency in children aged 3 years and older; once-weekly dosing via Y-shaped 40kD PEG modification.
• 珮金® (Telpegfilgrastim Injection) Telpegfilgrastim Injection for non-myeloid malignancy patients receiving myelosuppressive chemotherapy, reducing the incidence of febrile neutropenia; long-acting G-CSF formulated with 40kD Y-shaped branched PEG.
• 特尔立® (Molgramostim Injection) Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) for leukopenia and bone marrow hematopoietic dysfunction following tumor radiotherapy or chemotherapy.
• 特尔津® (Filgrastim Injection) Recombinant human granulocyte colony-stimulating factor (G-CSF) Injection for neutropenia following tumor chemotherapy; serves as the national standard substance raw material supplier in China.
• 特尔康® (Oprelvekin for Injection) Recombinant human Interleukin-11 (IL-11) for Injection for treatment of grade II–III thrombocytopenia following chemotherapy for solid tumors and non-myeloid leukemia; serves as the raw material supplier for the Chinese national standard substance of this product.

Quantifiable outcome

• 派格宾® is the world's first 40kD PEGylated interferon alfa-2b injection and first approved product for HBsAg sustained clearance combined with nucleos(t)ide analogs
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Aligos Therapeutics Inc.coreOEM/ Whitelabel/ Licensing Partner · 16 April 2026AMOYTOP Biotech entered into an exclusive license agreement with Aligos Therapeutics for the development and commercialization of pevifoscorvir sodium for chronic hepatitis B virus infection in Greater China (Mainland China, Taiwan, Hong Kong, and Macau). Aligos receives $25M upfront payment and is eligible for up to $420M in clinical, regulatory, and sales milestones plus tiered high single-digit royalties. The deal extends Aligos' cash runway into Q4 2026. Aligos retains all rights in US, Europe, Japan, South Korea and other global markets.
• Aligos Therapeutics Inc.coreStrategic or Co-development Partner · 22 July 2024AMOYTOP Biotech announced a clinical trial collaboration agreement with Aligos Therapeutics, Inc. (Nasdaq: ALGS) in July 2024, marking the beginning of their collaborative relationship.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Ascendis Pharma: Ascendis's TransCon hGH (lonapegsomatropin) is a long-acting growth hormone that competes in the same pediatric GHD and short stature indications as Amoytop's Inpegsomatropin, and represents the global benchmark for proprietary long-acting protein platforms.
• Sciwind Biosciences: Sciwind is a China-based clinical-stage biopharma developing long-acting biologics for metabolic disease, including HBV-related liver disease, making it a direct peer in the Chinese long-acting protein innovation space.
• Roche: Roche's Pegasys (PEG-IFN alfa-2a) is the most direct global competitor to Amoytop's Peginterferon alfa-2b in chronic hepatitis B, and Roche is also a major player in PEGylated biologics manufacturing — making it the closest analog in commercial HBV PEG-IFN franchise.
• Brii Biosciences: Brii Biosciences is a China/US infectious disease company focused on chronic hepatitis B functional cure, pursuing combination regimens that would compete directly with Amoytop's PEG-IFN-based cure approach.
• Tonghua Dongbao Pharmaceutical: Tonghua Dongbao is a leading Chinese recombinant protein drug manufacturer (notably insulin) and a disclosed investor in Amoytop, making it both a peer in recombinant biologics manufacturing and a capital relationship.
• Hybio Pharmaceutical: Hybio is a Chinese specialty PEGylation and peptide drug developer directly competing with Amoytop in long-acting injectable biologics and overlapping in oncology and endocrine therapeutic areas.
• Aligos Therapeutics: Aligos is a US-based HBV-focused developer with a clinical-stage capsid assembly modulator (ALG-000184) and pevifoscorvir sodium — both shared development interests with Amoytop under their 2024 collaboration and 2026 Greater China licensing agreement.
• GeneScience Pharmaceuticals: GeneScience is a leading Chinese recombinant human growth hormone specialist and the dominant domestic player in pediatric GHD — a direct competitor to Amoytop's Inpegsomatropin in the same indication and channel.

Broad incumbents

• Amgen: Amgen's Neulasta (pegfilgrastim) is the global long-acting G-CSF standard-of-care and a direct competitor to Amoytop's Telpegfilgrastim in oncology supportive care, while Amgen's broader biologics portfolio positions it as a benchmark large-molecule incumbent.

Regional players

• 3SBio: 3SBio is a leading Chinese biopharma with a recombinant protein portfolio spanning oncology supportive care (G-CSF), nephrology (epoetin), and is also developing long-acting formulations — making it a regional peer overlapping with Amoytop's portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amoytopbiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMOYTOP BIOTECH